Physician profile
Ryan Knox
NPI 1649520693
$6,685.30
in general payments reported to CMS, 2019-2025
12 companies · $234 in 2025
The $234 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,210 · 2020: $94.21 · 2021: $479 · 2022: $165 · 2023: $218 · 2024: $286 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $722 · Education: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $722.24 |
| Education | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $5,432.89 | 2019-2025 | Precision 1, Total30, Rocklatan |
| Johnson & Johnson Vision Care, INC. | $593.87 | 2019-2024 | |
| Bausch & Lomb Americas INC. | $215.04 | 2024-2025 | Vyzulta, Miebo, Xiidra |
| Sight Sciences, INC. | $111.94 | 2021 | |
| Allergan, INC. | $69.18 | 2021 | |
| Oyster Point Pharma, INC. | $58.17 | 2022-2023 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $54.15 | 2024 | Xdemvy |
| Biotissue Holdings INC. | $38.75 | 2021 | |
| Aerie Pharmaceuticals, INC. | $34.47 | 2019 | |
| Coopervision INC. | $29.33 | 2025 | Myday Contact Lens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $24.38 | 2019 | |
| Kala Pharmaceuticals, INC. | $23.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Knox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.